Cutaneous skull metastasis from uterine leiomyosarcoma: a case report
© Barbetakis et al; licensee BioMed Central Ltd. 2009
Received: 12 January 2009
Accepted: 11 May 2009
Published: 11 May 2009
Cutaneous metastases in the facial region occur in less than 0.5% of patients with metastatic cancer.
A 52-year-old woman who admitted with a lung and a skull skin nodule is presented. She had a known diagnosis of uterine leiomyosarcoma following an extended total hysterectomy two years ago. Excision biopsy of both nodules revealed metastatic disease.
The appearance of a cutaneous nodule in a patient with a history of uterine leiomyosarcoma might indicate a metastatic tumor lesion. Biopsy and immunohistochemistry are essential for correct diagnosis.
Leiomyosarcoma is a rare malignant neoplasm composed of cells demonstrating smooth muscle differentiation. Uterine leiomysarcoma accounts for 25–36% of uterine sarcoma and 1% of all malignancies and has a poor prognosis due to a high metastatic recurrence rate. They most commonly arise de novo; however, a minority (5%) may be associated with prior irradiation. The peak incidence occurs in the 30–40 age range and reaches a plateau in the middle age. Uterine leiomyosarcoma usually presents with features of vaginal bleeding (77–95%), pelvic pain (33%), uterine enlargement or a palpable pelvic mass (20–50%) .
The commonly reported sites of metastasis from leiomysarcoma are the lung, kidney and liver . Spread to the thyroid, brain, bone, skeletal muscle, heart, parotid gland and the oral cavity have also been reported [3–8]. Uterine leiomyosarcoma should be distinguished from benign uterine metastasizing leiomyoma which is diagnosed several years after myomectomy or hysterectomy with most commonly radiographic appearance of slow-growing solitary or multiple lung nodules.
In this report we describe an unusual case of uterine leiomyosarcoma metastasizing to the skull skin.
A 52-year-old multiparous woman was referred to our hospital in 2006 for post-menopausal abnormal uterine bleeding. She underwent an extended total hysterectomy, bilateral salpingho-oopherectomy and pelvic lymphadenectomy. Tumor cells infiltrated to the uterine serosa and invasion of the tumor cells to the lymphatic vessels was also noted. Immunohistochemistry demonstrated that the tumor cells were positive for a-smooth muscle actin. The patient was diagnosed with uterine leiomyosarcoma (intermediate grade) with positive pelvic lymph nodes. Postoperatively she received further treatment with combination chemotherapy composed of epirubicin, cyclophosphamide and carboplatin for 6 months. She also received radiation therapy with a total of 45 Gy to the pelvis.
Smooth muscle is a component of many tissues and organs. As a result, leiomyosarcoma can arise at almost any anatomic site in the human body. In women, approximately one third of leiomyosarcomas originate in the gastrointestinal tract, particularly the small bowel and colon and another one third are found in the uterus.
Stage, age, tumor size and delivery status of the patient were found to be the most important prognostic factors as regards survival. Interestingly, it seems that higher parity (up to three deliveries) had a negative influence on survival in cases of uterine sarcoma. The relationship between parity and survival in cases of uterine sarcoma should be evaluated more closely in larger series in the future .
Extrafascial hysterectomy with pelvic lymph node sampling with or without salpingo-oophorectomy is the surgical gold standard. Debate concerning removal of adnexa and the value of lymph node dissection (LND) is still ongoing . The survival of younger patients with leiomyosarcoma without oophorectomy has been better in one study which is very controversial. The rate of lymph node metastasis has been between 0–47%, and in some studies survival has not been significantly affected as regards LND . The role of adjuvant therapies is controversial. Radiotherapy (RT) seems to improve local control but not survival. Adjuvant chemotherapy (CT) does not decrease the risk of metastatic spread or improve survival. In recurrent uterine sarcomas the response rates in different chemotherapeutic regimens have been between 0–57%. However, the conclusion after a review of the literature was that it is reasonable to offer palliative CT to patients with advanced uterine sarcoma. The effects of hormone therapy in cases of recurrent uterine sarcoma have been assessed in only a few studies .
A case of uterine leiomyosarcoma with synchronous lung and cutaneous skull metastasis is presented.
Lung and breast cancers are the commonest epithelial malignancies metastasizing to the skin in men and women respectively. Clinically, cutaneous metastases manifest as nodules, ulceration, cellulitis like lesions, bullae or fibrotic processes .
Cutaneous metastases as a first sign of internal malignancy occur infrequently. More commonly, they are early indicators of metastatic disease . Diagnosis may delay several months, unless the skin lesion grows rapidly or other sites such as the lung or liver affected by tumor spread. In our case, the cutaneous metastasis was diagnosed simultaneously with the lung lesion.
Uterine leiomyosarcoma has a strong metastatic potential to distant sites, because of its aggressiveness and propensity for hematogenous spread. Cutaneous metastasis although rare indicates tumor relapse. Early detection requires high index of suspicion. Therefore, close inspection of new skin lesions in patients with history of malignancy is imperative and diagnostic biopsy is essential.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Iwamoto I, Fujino T, Higashi Y, Tsuji T, Nakamura N, Komokata T, Douchi T: Metastasis of uterine leiomyosarcoma to the pancreas. J Obstet Gynaecol Res. 2005, 31 (6): 531-534. 10.1111/j.1447-0756.2005.00344.x.View ArticlePubMed
- Rose PG, Piver MS, Tsukada Y, Lau T: Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer. 1989, 63: 935-938. 10.1002/1097-0142(19890301)63:5<935::AID-CNCR2820630525>3.0.CO;2-9.View ArticlePubMed
- Leath CA, Huh WK, Straughn JM, Conner MG: Uterine leiomyosarcoma metastatic to the thyroid. Obstet Gynecol. 2002, 100: 1122-1124. 10.1016/S0029-7844(02)02191-9.View ArticlePubMed
- Wronski M, de Palma P, Arbit E: Leiomyosarcoma of the uterus metastatic to the brain: case report and review of the literature. Gynaecol Oncol. 1994, 54: 237-241. 10.1006/gyno.1994.1201.View Article
- Nanassis K, Alexiadou-Rudolf C, Tsitsopoulos P: Spinal manifestation of metastasizing leiomyosarcoma. Spine. 1999, 24: 987-989. 10.1097/00007632-199905150-00011.View ArticlePubMed
- O'Brien JM, Brennan DD, Taylor DH, Holloway DP, Hurson B, O'Keane JC, Eustace SJ: Skeletal muscle metastasis from uterine leiomyosarcoma. Skeletal Radiol. 2004, 33: 655-659. 10.1007/s00256-004-0787-5.View ArticlePubMed
- Martin JL, Boak JG: Cardiac metastasis from uterine leiomyosarcoma. J Am Coll Cardiol. 1983, 2: 383-386.View ArticlePubMed
- Saiz AD, Sachdev U, Brodman ML, Deligdisch L: Metastatic uterine leiomyosarcoma presenting as a primary sarcoma of the parotid gland. Obstet Gynecol. 1998, 92: 667-668. 10.1016/S0029-7844(98)00137-9.View ArticlePubMed
- Sleijfer S, Seynaeve C, Verweij J: Gynaecological sarcomas. Curr Opin Oncol. 2007, 19 (5): 492-496. 10.1097/CCO.0b013e3282748eaa.View ArticlePubMed
- Gadducci A, Cosio S, Romanini A, Genazzani AR: The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008, 65: 129-142. 10.1016/j.critrevonc.2007.06.011.View ArticlePubMed
- Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS: Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol. 2003, 91: 209-212. 10.1016/S0090-8258(03)00478-5.View ArticlePubMed
- Koivisto-Korrander R, Butzow R, Koivisto AM, Leminen A: Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: Experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol. 2008, 111: 74-81. 10.1016/j.ygyno.2008.06.002.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.